Targeting the CTLA-4 and PD-1 "checkpoints" is an effective treatment for a number of cancers. In this issue of Immunity, Hui et al. reveal that interaction between a CTLA-4 ligand, CD80, and its counterpart in the PD-1 pathway, PD-L1, affects both PD-1 and CTLA-4 function, raising new questions about the biological effects of using checkpoint inhibitors alone and in combination.

中文翻译：

---

二聚体不会永远存在：CD80 与 PD-L1 分裂。


针对 CTLA-4 和 PD-1“检查点”是多种癌症的有效治疗方法。在本期《免疫》中，Hui 等人。揭示 CTLA-4 配体 CD80 与其在 PD-1 通路中的对应物 PD-L1 之间的相互作用影响 PD-1 和 CTLA-4 功能，这引发了有关单独使用检查点抑制剂的生物学效应的新问题组合起来。